Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bezmialem Vakif University
ClinicalTrials.gov Identifier:
NCT02009592
First received: November 28, 2013
Last updated: May 15, 2014
Last verified: May 2014